Congress Scientific Watch

From ASCO 2023 Annual Meeting:
Progression-free and overall survival in metastatic hormone receptor-positive, HER2- negative patients are better with sacituzumab govitecan than chemotherapy  

From ASCO 2023 Annual Meeting:
The DESTINY-PanTumor02 study indicates that patients whose solid tumours express HER2 may benefit from treatment with trastuzumab deruxtecan  

From ASCO 2023 Annual Meeting:
Vorasidenib extends progression-free survival and delays the requirement for further intervention in patients with IDH-mutant WHO grade 2 diffuse glioma

From ASCO 2023 Annual Meeting:
Autologous anti-CD19 CAR T-cell therapy boosts overall survival in patients with early relapsed or refractory large B-cell lymphoma

From ASCO 2023 Annual Meeting:
Survival outcomes for persistent, recurrent or metastatic cervical cancer are significantly improved with the use of pembrolizumab alongside chemotherapy, regardless of bevacizumab therapy

From ASCO 2023 Annual Meeting:
Interim KEYNOTE-671 findings demonstrate an event-free survival benefit with use of pembrolizumab before and after surgery for patients undergoing treatment for early-stage, non-small-cell lung cancer  

From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival 

From ESMO Breast Cancer 2023:
Patients who do not achieve a complete response to neoadjuvant therapy for early-stage triple-negative breast cancer and have ctDNA after additional capecitabine are at high risk of recurrence 

From ESMO Breast Cancer 2023:
Patients with ER-low breast cancer may have disease with similar behaviours to those of their ER-negative counterparts

From ESMO Breast Cancer 2023:
Obesity is associated with poorer disease-free survival than normal weight after postmenopausal hormone receptor-positive breast cancer for women younger than 60 years, but may not affect older patients 

From ESMO Breast Cancer 2023:
The addition of capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with hormone receptor-positive, HER2-negative advanced breast cancer resistant to aromatase inhibitors

From the 2023 AACR Annual Meeting:
RLY-2608, a mutant-selective PI3Kα inhibitor, may offer patients with PIK3CA-mutant solid tumours a chance of treatment without experiencing the toxic effects of non-selective PI3Kα inhibition